AstraZeneca announces their new advances of infectious disease protection at IDWeek 2024
Posted on October 20, 2024
AstraZeneca shares that they will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 October 2024. They will highlight progress in advancing novel immunisations against infectious diseases of high unmet need and share real-world evidence showing the burden of respiratory viral infections and the continued need for protection.
Iskra Reic, Executive Vice President of Vaccines & Immune Therapies, AstraZeneca, said: “The data being presented at IDWeek demonstrate our commitment to addressing the impact of infectious diseases, notably our progress in developing our vaccine and antibody candidates against viral and bacterial pathogens, including IVX-A12, the first potential combination RSV/hMPV vaccine, and AZD5148 against C. diff infections. The advancement of IVX-A12 builds on our scientific leadership in RSV, with data being presented on Beyfortus demonstrating how, in its first season, it has delivered significant real-world impact in protecting a broad infant population against the disease, with millions more children set to benefit this season.”
Data in RSV, combination vaccines, C. diff and influenza
Data will be presented on Beyfortus, AstraZeneca’s long-acting antibody for the prevention of RSV disease, showing that Beyfortus does not interfere with RSV detection by rapid antigen tests enabling accurate diagnosis to support clinical management. Additional data, presented by our partner Sanofi, confirm the significant real-world effectiveness of Beyfortus in reducing RSV disease and hospitalisations in infants. These data build on recent evidence, including from the US Advisory Committee on Immunisation Practices, demonstrating Beyfortus was associated with a 90% reduction in RSV-associated hospitalisations in its first season.
Related Topics and Keywords
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy